

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Midostaurin for treating advanced systemic mastocytosis [ID1573]

Final stakeholder list of consultees and commentators

| Consultees | Commentators (no right to submit or appeal) |
|---|--|
| <p><u>Company</u></p> <ul style="list-style-type: none"> • Novartis Pharmaceuticals (midostaurin) <p><u>Patient/carer group</u></p> <ul style="list-style-type: none"> • African Caribbean Leukaemia Trust (ACLT) • Anthony Nolan • Black Health Agency • Bloodwise • Cancer Black Care • Cancer Equality • Cancer52 • Chronic Lymphocytic Leukaemia Support Association • Chronic Myeloid Leukaemia Support Group • DKMS • Genetic Alliance UK • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Leukaemia Cancer Society • Leukaemia CARE • Lymphoma Action • Macmillan Cancer Support • Maggie's Centres • Marie Curie • MPN Voice • Muslim Council of Britain • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • UK Mastocytosis Support Group <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Genetic Nurses and | <p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services – Jehovah's Witnesses • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Blood and Transplant • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord-UK (imatinib) • Aurobindo Pharma - Milpharm (imatinib) • Bristol-Myers Squibb Pharmaceuticals (dasatinib) • Dr. Reddy's Laboratories (imatinib) • Generics UK (imatinib) • Intrapharm Laboratories (imatinib) • Janssen-Cilag (cladribine) • Lipomed (cladribine) • Merck Sharp & Dohme (cladribine, interferon alfa-2b) • Novartis Pharmaceuticals (imatinib, |

| Consultees | Commentators (no right to submit or appeal) |
|---|--|
| <p>Counsellors</p> <ul style="list-style-type: none"> • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society for Gene and Cell Therapy • British Society for Genetic Medicine • British Society for Haematology • British Society for Human Genetics • Cancer Research UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Chronic Lymphocytic Leukaemia Forum • UK Clinical Pharmacy Association • UK Genetic Testing Network • UK Health Forum • UK Oncology Nursing Society • United Kingdom Primary Immunodeficiency Network <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Greater Preston CCG • NHS Hartlepool and Stockton-on-Tees CCG • Welsh Government | <p>nilotinib)</p> <ul style="list-style-type: none"> • Rivopharm UK (imatinib) • Roche (interferon alfa-2a) • Sandoz (imatinib) • Wockhardt UK (imatinib) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Cystic Fibrosis & Genetic Disorders Group • Cochrane Haematological Malignancies Group • Genomics England • Institute of Cancer Research • Leuka • Leukaemia Busters • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Final stakeholder list for the technology appraisal of midostaurin for treating advanced systemic mastocytosis ID1573. Issue date: December 2019

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care, the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.